<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80755">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097147</url>
  </required_header>
  <id_info>
    <org_study_id>VLZ-MD-24</org_study_id>
    <nct_id>NCT02097147</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel-Group Study Evaluating The Sexual Functioning of Healthy Adults After Receiving Multiple-Dose Regimens of Vilazodone, Paroxetine, or Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of vilazodone, paroxetine and placebo on sexual function in sexually
      active healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Change in Changes in Sexual Functioning Questionnaire (CSFQ) total score</measure>
    <time_frame>From Baseline to Day 35</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The CSFQ is a subject-rated scale designed to measure changes in sexual function and is a structured, self-report, 14-item questionnaire, that measures sexual functioning as a total score (all 14 items), and on the subscales of pleasure, desire/frequency, desire/interest, arousal, and orgasm, rated on a 5 point scale, with each item rated from 1 to 5, and a total score range of 14 to 70. Lower scores are associated with worsened sexual functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects meeting criteria for sexual dysfunction.</measure>
    <time_frame>5 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of subjects meeting criteria for sexual dysfunction (ie, CSFQ &lt;=47 for males and &lt;=41 for females) at any 2 consecutive visits during the double-blind treatment period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Vilazodone 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vilazodone 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days,  followed by vilazodone 40 mg once daily for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 35 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilazodone 20 mg</intervention_name>
    <description>Oral administration, once per day.</description>
    <arm_group_label>Vilazodone 20 mg</arm_group_label>
    <other_name>Viibyrd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilazodone 40 mg</intervention_name>
    <description>Oral administration, once per day.</description>
    <arm_group_label>Vilazodone 40 mg</arm_group_label>
    <other_name>Viibryd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine 20 mg</intervention_name>
    <description>Oral administration, once per day.</description>
    <arm_group_label>Paroxetine 20 mg</arm_group_label>
    <other_name>Paxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration, once per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female, aged 18 through 45 years, inclusive

          -  Currently sexually active

          -  If female, non pregnant and agree to use acceptable for of contraception during

          -  If male, be sterile or have partner use contraception.

        Exclusion Criteria:

          -  Have sexual dysfunction

          -  Have history of diagnosis or treatment of any disorder related to sexual functioning.

          -  Clinically significant disease state, in the opinion of the examining physician, in
             any body system

          -  History of alcohol or other substance abuse or dependence within the previous 5 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maju Mathews, MD</last_name>
    <role>Study Director</role>
    <affiliation>Forest Laboratories</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Beaird, Pharm.D</last_name>
    <phone>1-800-678-1605</phone>
    <phone_ext>66297</phone_ext>
    <email>FRXClinTrials@frx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Forest Investigative Site 001</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 002</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 003</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forest Investigative Site 004</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viibryd</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
